Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CG-53135; CG53135-05; FGF 20; Fibroblast growth factor-20; rhFGF-20

Latest Information Update: 17 Mar 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CuraGen Corporation
  • Class Anti-inflammatories; Expectorants; Fibroblast growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Stomatitis

Most Recent Events

  • 10 Aug 2007 CuraGen completes enrolment in the CLN-12 trial for oral mucositis in the US
  • 01 Jun 2006 CuraGen has initiated enrolment in the CLN-12 trial for oral mucositis in the US, evaluating a single dose of velafermin
  • 24 Feb 2006 Data from a media release have been added to the adverse events and Mouth disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top